|I. General information|
|Background:||The A3 subclone was derived from a Jurkat cell line obtained from the laboratory of Gerald Crabtree at Stanford University.|
|Species:||Homo sapiens, human|
|Disease:||acute T cell leukemia|
|DNA Profile:||Amelogenin: X,Y
Cobioer’s Cell Line Authentication Service
|Culture Medium:||RPMI-1640 +10%FBS
We strongly suggest to purchase the complete medium from Cobioer.
|Comments:||The Jurkat cells were treated with Fas Antibody and isolated by limiting dilution to obtain a cell line that had a low spontaneous rate of resistance to Fas-medicated apoptosis.The resulting wild-type A3 subclone is very sensitive to Fas-mediated apoptosis.Wild-type A3 cells were made neomycin resistant and treated with three cycles of exposure to the frameshifting mutagen ICR-191 to isolate clones harboring recessive mutations that were resistant to killing by Fas antibody.
ICR-191 treated clones were serially diluted in 96-well plates in the presence of Fas Antibody for 3 to 5 weeks.Two of these ICR-191 treated clones have been deposited at the ATCC. They are I 9.2 (ATCC CRL-2571), a clone with a mutation in the cysteine protease caspase-8/FLICE and I 2.1 (ATCC CRL-2572), a clone with a mutation in the adaptor FADD.
For more information, please contact Cobioer (4008-750-250).